
Pharmacally
Health Tidings
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Health Tidings
Health TidingsKaliVir Reports 71% Response Rate With VET3-TGI in Skin CancersKaliVir Immunotherapeutics has reported a 71% objective response rate with investigational oncolytic immunotherapy VET3-TGI in patients with advanced cutaneous malignancies who progressed following anti-PD-1/PD-L1 treatment.Fact-Checked
Health TidingsOnchilles Pharma Advances in Situ Cancer Vaccine Strategy with N17350Onchilles Pharma has reported preliminary Phase 1/2 findings for N17350, with five non-injected tumour lesions becoming undetectable in one patient with Merkel cell carcinoma.Fact-Checked
Health TidingsOncoC4 Reports 33% Response Rate with Cesalatamig in NSCLCOncoC4 reported a 33% objective response rate and 90% disease control rate with its investigational PD-1/VEGF bispecific antibody cesalatamig at 10 mg/kg in previously treated PD-(L)1-resistant or refractory…Fact-Checked
Health TidingsLilly Expands Zepbound and Foundayo Access Through Hims & HersEli Lilly has partnered with Hims & Hers Health to expand access to its FDA-approved obesity medicines, Zepbound and Foundayo, through the telehealth platform.Fact-Checked
Health TidingsEdgewise Submits EDG-7500 Phase 3 Protocol After FDA MeetingEdgewise Therapeutics has submitted the Phase 3 STRATUS-HCM protocol for EDG-7500 following a productive FDA End-of-Phase 2 meeting.Fact-Checked
Health TidingsChai Adds Roche to Its Expanding AI Drug Discovery NetworkChai Discovery has partnered with Roche to apply its AI-powered protein design models across multiple drug discovery programs.Fact-Checked
Health TidingsResolution Reports 42% Lower Clinical Event Risk in ESLD, Advances RTX001 Towards US Pivotal TrialResolution Therapeutics reported a 42% relative reduction in composite clinical events with RTX001 in the six-month interim analysis of its Phase I/II EMERALD trial.Fact-Checked
Health TidingsPrecision Wins DSMB Support to Expand PBGENE-DMD TrialPrecision BioSciences has received a positive DSMB safety review for PBGENE-DMD, supporting additional patient dosing and completion of Part 1 enrollment in the Phase 1/2 FUNCTION-DMD study.Fact-Checked
Mergers & AcquisitionsBoehringer Ingelheim and China’s Sino Strike $7.4B Oncology DealBoehringer Ingelheim has secured options on six preclinical oncology programs from Sino Biopharmaceutical, expanding its ADC and T-cell engager pipeline through an agreement featuring US$358 million in upfront…Fact-Checked
Health TidingsSK Submits sNDA for Cenobamate (XCOPRI) in PGTCSK Biopharmaceuticals submits FDA sNDA for cenobamate (XCOPRI) in PGTC seizures based on Phase 3 trial data showing a 71.9% seizure reduction.Fact-Checked
Health TidingsHUTCHMED Gains Second FDA Orphan Status for Sovleplenib in AIHAHUTCHMED has received its second FDA Orphan Drug Designation for sovleplenib, this time for autoimmune hemolytic anemia (AIHA).Fact-Checked
Mergers & AcquisitionsEvommune Bets on EVO570 and VAV1 Degradation with $1.1B Hinova DealEvommune has secured worldwide rights outside Greater China to Hinova’s investigational oral VAV1 molecular glue degrader EVO570 in a deal worth up to $1.1 billion.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.